Oral vancomycin therapy in a child with primary sclerosing cholangitis and severe ulcerative colitis

Cynthia Buness, Keith Lindor, Tamir Miloh

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Primary sclerosing cholangitis (PSC), a rare progressive liver disease characterized by cholestasis and bile duct fibrosis, has no accepted, effective therapy known to delay or arrest its progression. We report a 15 year old female patient diagnosed with PSC and moderate chronic active ulcerative colitis (UC) who achieved normalization of her liver enzymes and bile ducts, and resolution of her UC symptoms with colonic mucosal healing, after treatment with a single drug therapy of the antibiotic oral vancomycin. We postulate that the oral vancomycin may be acting both as an antibiotic by altering the intestinal microbiome and as an immunomodulator. Oral vancomycin may be a promising treatment for PSC that needs to be further studied in randomized trials.

Original languageEnglish (US)
Pages (from-to)210-213
Number of pages4
JournalPediatric Gastroenterology, Hepatology and Nutrition
Volume19
Issue number3
DOIs
StatePublished - Jan 1 2016

Keywords

  • Liver diseases
  • Primary sclerosing cholangitis
  • Ulcerative colitis
  • Vancomycin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Oral vancomycin therapy in a child with primary sclerosing cholangitis and severe ulcerative colitis'. Together they form a unique fingerprint.

  • Cite this